Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of$ 0.18. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.13 per share when it actually produced a loss of $0.15, delivering a surprise of -15.38%.Over the last four quarters, ...